The link wasn't included because I have no patience having a post dinged by yahoo because I included a link within. Any pointers on how you got yours past the YH nanny?
A small study - released in the past week - entitled Near-infrared (NIR) perfusion angiography in minimally invasive colorectal surgery, used Novadaq's PINPOINT in surgery on 30 consecutive patients. The mantra continues - no leaks. Go PILLAR.
It doesn't appear to be an articulating type. Instead of a reload cartridge the whole shaft is the reload.
Arun mentioned that one selling point of PINPOINT was that it serves as a replacement endoscopic system and not just another added piece of equipment. I hadn’t heard that mentioned before.
Another item presented that I found interesting was that a second generation PINPOINT device will be revealed at SAGES (April 2-5). Arun intimated that their market strategy included introduction of upgraded versions of current products thus allowing higher pricing power.
Note that for the ETS Flex more than one handle per procedure was sometimes used, upping the cost per patient for the gastric bypass procedure in this study. Your mileage may vary.
Just poking around I found a 2011 study on cost comparison of staplers in gastric bypass by J. K. Champion MD and Mike Williams MD. The staplers compared were the USSC Endo-GIA Universal six row stapler and the Ethicon ETS-Flex six row stapler. The table from the study doesn’t breakdown the individual handle and cartridge costs but lumps them together. So the per patient cost was $1544.32 for the Endo-GIA and $1225.32 for the ETS-Flex.
From the study:
Endo-GIA (n=50) ETS-Flex (n=50)
Total # cartridges 442 448
Total # handles 50 81
Total Cost($US) $77,215.78 $61,266.22
Verification via eSutures prices -- for Ethicon ETS FLEX (45mm)
Cartridges ($1140 / Box of 12) $95 ea.
81 X $290 = $23,490
448 X $95 = $42,560
Total = $66,050
Close enough at today's prices.
To be fair, Cardica does seem to fail to explain the number of design iterations and length of time necessary to get their products to market. Just when you think they have it done, it's "Oh, by the way, we need to re-engineer the stapler to make it like more like what the surgeons are use to using ...and we need to get FDA approval to use a different plastic."
On the other hand, I'm sure getting a state-of-the-art medical device functional and ready for the surgery is not easy to accomplish.
Are you claiming that it wasn't peer reviewed? This was a study published in the "Journal of Minimally Invasive Gynecology". I would encourage you write them if you have evidence of fraud. Be sure to cc Intuitive and Dr. Martino.
And the results of the Pillar II trial will be published within 60 days, before the SAGES (The Society of American Gastrointestinal and Endoscopic Surgeons) meeting, April 2-5.
You are correct that the Exchange 30 was only approved for appendix and intestinal procedures. But, like any other FDA approved device, once approved there is nothing to prevent a surgeon from using it "off-label"(other than liability issues, perhaps). Doctors do this with drugs all the time.
However, Cardica cannot advertize or promote any off-label use.
Also, shorter hospital stays, less blood loss.
Comments, Herb Greenberg?
No link, see yahoo company news for ISRG (2-5-2014).
The key to isrg not being taken out was that isrg's price was always just ahead of an acquiring company's comfort zone. It was easier for a buyer to take a pass on potential future profits than be second guessed by current shareholders and analysts due to a perceived overpayment.
I'm hoping the same thing will happen with nvdq. Nvdq's management knows what they have, I don't think they will sell cheaply.